Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Galmarini

Showing results (11-20 of 129) with videos related to

Pageof 13
Sort By:
Idrugs : the Investigational Drugs Journal|October 4, 2006
Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumorCarlos M Galmarini
Molecular Cancer Therapeutics|July 22, 2010
A review of trabectedin (ET-743): a unique mechanism of actionMaurizio D'Incalci, Carlos M Galmarini
European Review for Medical and Pharmacological Sciences|July 25, 2020
Artificial intelligence: a disruptive tool for a smarter medicineC M Galmarini, M Lucius
Drugs of Today (Barcelona, Spain : 1998)|November 16, 2010
Cabazitaxel, a new taxane with favorable propertiesB P Bouchet, C M Galmarini
The Journal of Clinical Endocrinology and Metabolism|November 1, 1984
Ideal conditions for hydrolysis of androstanediol 3 alpha, 17 beta-diol glucuronide in plasmaR Horton, D Endres, M Galmarini
Current Drug Targets|July 18, 2003
Drug resistance to cytotoxic nucleoside analoguesL Jordheim, C M Galmarini, C Dumontet
Current Cancer Drug Targets|January 29, 2008
Tubulin folding pathways: implication in the regulation of microtubule dynamicsA Beghin, C M Galmarini, C Dumontet
Investigative Urology|March 1, 1973
Experimental autoimmune damage to rabbit male accesory glandsC Yantorno, E Vottero-Cima, M Galmarini
Investigative Ophthalmology|March 1, 1973
Experimental autoimmune damage to rabbit male accessory glandsC Yantorno, E Vottero-Cima, M Galmarini
Bulletin Du Cancer|April 12, 2005
[Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues]Lars P Jordheim, Carlos M Galmarini, Charles Dumontet
Pageof 13

Showing results (11-20 of 129) with videos related to

Sort By:
Pageof 13
Idrugs : the Investigational Drugs Journal|October 4, 2006
Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumorCarlos M Galmarini
Molecular Cancer Therapeutics|July 22, 2010
A review of trabectedin (ET-743): a unique mechanism of actionMaurizio D'Incalci, Carlos M Galmarini
European Review for Medical and Pharmacological Sciences|July 25, 2020
Artificial intelligence: a disruptive tool for a smarter medicineC M Galmarini, M Lucius
Drugs of Today (Barcelona, Spain : 1998)|November 16, 2010
Cabazitaxel, a new taxane with favorable propertiesB P Bouchet, C M Galmarini
The Journal of Clinical Endocrinology and Metabolism|November 1, 1984
Ideal conditions for hydrolysis of androstanediol 3 alpha, 17 beta-diol glucuronide in plasmaR Horton, D Endres, M Galmarini
Current Drug Targets|July 18, 2003
Drug resistance to cytotoxic nucleoside analoguesL Jordheim, C M Galmarini, C Dumontet
Current Cancer Drug Targets|January 29, 2008
Tubulin folding pathways: implication in the regulation of microtubule dynamicsA Beghin, C M Galmarini, C Dumontet
Investigative Urology|March 1, 1973
Experimental autoimmune damage to rabbit male accesory glandsC Yantorno, E Vottero-Cima, M Galmarini
Investigative Ophthalmology|March 1, 1973
Experimental autoimmune damage to rabbit male accessory glandsC Yantorno, E Vottero-Cima, M Galmarini
Bulletin Du Cancer|April 12, 2005
[Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues]Lars P Jordheim, Carlos M Galmarini, Charles Dumontet
Pageof 13